Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Electric field therapy plus immunotherapy tested for tough lung cancers

NCT ID NCT06558799

Disease control Sponsor: NovoCure GmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a wearable device that sends low-intensity electric fields to tumors, combined with the immunotherapy drug pembrolizumab, in people with advanced non-small cell lung cancer that had already been treated with chemotherapy and immunotherapy. The goal was to see if this combination could help patients live longer. The study was stopped early, and only 31 people took part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

31 people

The number who actually took part.

Started

Oct 2024

Finished

Feb 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

INCLUSION CRITERIA: * ≥18 years of age * Histologically or cytologically confirmed diagnosis of NSCLC. * Documented positive tumor PD-L1 expression (TPS≥1%). * Eastern Cooperative Oncology Group (ECOG) Score of 0-1. * Diagnosis of radiological progression while on or after first platinum-based systemic therapy administered for advanced or metastatic disease. * Subjects must have received one line of PD-1/PD-L1 inhibitor therapy for advanced or metastatic NSCLC. PD-1/PD-L1 inhibitor may have been given alone or in combination with other therapy. * Subjects who received PD-1/PD-L1 inhibitor for advanced disease, must have had a best response on PD-1/PD-L1 inhibitor of stable disease (SD), partial response (PR) or complete response (CR). * Subjects must have experienced disease progression more than 84 days following Cycle 1 Day 1 (C1D1) of their most recent PD-1/PD-L1 inhibitor therapy. EXCLUSION CRITERIA - All individuals meeting any of the following exclusion criteria will be excluded from study participation: * Mixed small cell and NSCLC histology. * Subject must not have leptomeningeal disease or spinal cord compression. * Subject must not have untreated, symptomatic brain metastases, or residual neurological dysfunction. * Subjects must not have received more than one line of PD-1/PD-L1 inhibitor for advanced disease. * Subjects with a known sensitizing mutation for which the Food and Drug Administration (FDA)-approved targeted therapy for NSCLC exists (e.g., EGFR, ALK, ROS1) are excluded unless previously received at least one of the approved therapy(ies). * Subjects with more than 2 lines of therapy in the advanced setting. * Pregnant or breastfeeding. * Implantable electronic medical devices (e.g. pacemaker, defibrillator) in the upper torso. * Known allergies to medical adhesives or hydrogel.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer (NSCLC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Neoplasm Metastasis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer (NSCLC)

Contacts and locations

Locations

  • AO SM Misericordia di Perugia

    Perugia, 06129, Italy

  • AOUS Policlinico Le Scotte U.O.C. Immunoterapia Oncologica

    Siena, 53100, Italy

  • APHP - Hôpital Ambroise-Paré

    Boulogne-Billancourt, 92100, France

  • Centre Hospitalier Intercommunal de Cornouaille Service D'oncologie Médicale

    Quimper, 29107, France

  • Centre Léon Berard Service D'oncologie Médicale

    Lyon, 69373, France

  • Centre hospitalier intercommunal de Créteil Service de Pneumologie

    Créteil, 94010, France

  • Clínica Universidad de Navarra

    Pamplona, 31008, Spain

  • Clínica Universidad de Navarra, Madrid

    Madrid, 28027, Spain

  • FN Motol

    Prague, 150 06, Czechia

  • General University Hospital in Prague, Clinic of Oncology

    Prague, 128 08, Czechia

  • Hospital Regional Universitario de Malaga (Hospital Civil)

    Málaga, Spain

  • Hospital Universitario Arnau de Vilanova

    Lleida, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

  • Hospital Universitario del Vinalopó

    Elche, 03293, Spain

  • Humanitas Gavazzeni Bergamo-U.O.Farmacia-Edificio D Piano -1

    Bergamo, Italy

  • Hôpital Européen Marseille

    Marseille, 13003, France

  • Hôpital Privé du Confluent Service D'oncologie Médicale

    Nantes, 44277, France

  • Istituto Europeo di Oncologia

    Milan, 20141, Italy

  • MS Pneumed Janusz Milanowski, Katarzyna Szmygin-Milanowska Spó?ka Jawna

    Lublin, Poland

  • Montpellier University Hospital

    Montpellier, 34295, France

  • Pratia MCM Kraków

    Krakow, Poland

  • Rijnstate Ziekenhuis

    Arnhem, Netherlands

  • Universitätsklinik f. Innere Medizin III

    Salzburg, Austria

  • Vitkovicka Nemocnice

    Ostrava, 1192, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.